These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 9247310

  • 21. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
    Nishimura R, Moriyama K, Yasukawa K, Mundy GR, Yoneda T.
    J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
    [Abstract] [Full Text] [Related]

  • 22. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G, Küster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC.
    J Immunol; 1998 Dec 01; 161(11):6347-55. PubMed ID: 9834125
    [Abstract] [Full Text] [Related]

  • 23. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
    Yoshida S, Harada T, Iwabe T, Taniguchi F, Mitsunari M, Yamauchi N, Deura I, Horie S, Terakawa N.
    Hum Reprod; 2004 Aug 01; 19(8):1821-5. PubMed ID: 15166129
    [Abstract] [Full Text] [Related]

  • 24. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
    Peters M, Blinn G, Solem F, Fischer M, Meyer zum Büschenfelde KH, Rose-John S.
    J Immunol; 1998 Oct 01; 161(7):3575-81. PubMed ID: 9759879
    [Abstract] [Full Text] [Related]

  • 25. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
    Arita Y, Buffolino P, Coppock DL.
    Exp Cell Res; 1998 Aug 01; 242(2):381-90. PubMed ID: 9683525
    [Abstract] [Full Text] [Related]

  • 26. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion.
    Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grötzinger J, Rose-John S.
    Nat Biotechnol; 1997 Feb 01; 15(2):142-5. PubMed ID: 9035138
    [Abstract] [Full Text] [Related]

  • 27. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism.
    Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S.
    Mol Ther; 2004 Dec 01; 10(6):1085-95. PubMed ID: 15564140
    [Abstract] [Full Text] [Related]

  • 28. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells.
    Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R.
    Int Immunopharmacol; 2004 May 01; 4(5):679-91. PubMed ID: 15120652
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells.
    Gooch JL, Herrera RE, Yee D.
    Cell Growth Differ; 2000 Jun 01; 11(6):335-42. PubMed ID: 10910100
    [Abstract] [Full Text] [Related]

  • 31. Redundant functions of B-Myb and c-Myb in differentiating myeloid cells.
    Golay J, Broccoli V, Borleri GM, Erba E, Faretta M, Basilico L, Ying GG, Piccinini G, Shapiro LH, Lovrić J, Nawrath M, Mölling K, Rambaldi A, Introna M.
    Cell Growth Differ; 1997 Dec 01; 8(12):1305-16. PubMed ID: 9419419
    [Abstract] [Full Text] [Related]

  • 32. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid.
    Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA.
    J Rheumatol; 1997 Aug 01; 24(8):1510-6. PubMed ID: 9263143
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
    Moran DM, Mayes N, Koniaris LG, Cahill PA, McKillop IH.
    Liver Int; 2005 Apr 01; 25(2):445-57. PubMed ID: 15780071
    [Abstract] [Full Text] [Related]

  • 35. Effect of soluble interleukin-6 receptor on interleukin-6 synthesis in human skin fibroblasts.
    Cichy J, Rose-John S, Pryjma J, Travis J.
    Biochem Biophys Res Commun; 1996 Oct 14; 227(2):318-21. PubMed ID: 8878515
    [Abstract] [Full Text] [Related]

  • 36. Antibodies to rat soluble IL-6 receptor stimulate B9 hybridoma cell proliferation.
    Thibault V, Richards CD, Botelho F, Gauldie J.
    FEBS Lett; 1997 May 19; 408(2):182-6. PubMed ID: 9187363
    [Abstract] [Full Text] [Related]

  • 37. Purification of soluble murine interleukin 5 (IL-5) receptor alpha expressed in Chinese hamster ovary cells and its action as an IL-5 antagonist.
    Tsuruoka N, Yamashiro K, Tsujimoto M.
    Arch Biochem Biophys; 1993 Nov 15; 307(1):133-7. PubMed ID: 8239650
    [Abstract] [Full Text] [Related]

  • 38. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G.
    Cancer Res; 1996 Sep 15; 56(18):4213-8. PubMed ID: 8797594
    [Abstract] [Full Text] [Related]

  • 39. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease.
    Ikeda K, Kinoshita M, Tagaya N, Shiojima T, Taga T, Yasukawa K, Suzuki H, Okano A.
    Brain Res; 1996 Jul 08; 726(1-2):91-7. PubMed ID: 8836549
    [Abstract] [Full Text] [Related]

  • 40. Lack of increased serum interleukin-6 and soluble IL-6 receptor concentrations in patients with thyroid diseases following recombinant human interferon alpha therapy.
    Minelli R, Girasole G, Pedrazzoni M, Giuliani N, Schianchi C, Giuberti T, Braverman LE, Salvi M, Roti E.
    J Investig Med; 1996 Aug 08; 44(6):370-4. PubMed ID: 8795300
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.